TERUMO CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,610 JPY | +0.50% |
|
+2.84% | +12.96% |
| Apr. 12 | Penumbra, Inc. : The underdog in healthcare |  |
| Mar. 18 | Frontier Field Co., Ltd. announced that it has received funding from Terumo Corporation | CI |
| Sales 2024 * | 905B 5.78B | Sales 2025 * | 971B 6.2B | Capitalization | 3,857B 24.63B |
|---|---|---|---|---|---|
| Net income 2024 * | 108B 692M | Net income 2025 * | 125B 800M | EV / Sales 2024 * | 4.29 x |
| Net Debt 2024 * | 23.33B 149M | Net cash position 2025 * | 55.65B 355M | EV / Sales 2025 * | 3.91 x |
| P/E ratio 2024 * |
35.8
x | P/E ratio 2025 * |
30.9
x | Employees | 30,207 |
| Yield 2024 * |
0.84% | Yield 2025 * |
0.92% | Free-Float | 95.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Terumo Corporation
More recommendations
More press releases
More news
| 1 day | +0.50% | ||
| 1 week | +2.84% | ||
| Current month | -4.34% | ||
| 1 month | -6.08% | ||
| 3 months | +5.84% | ||
| 6 months | +32.34% | ||
| Current year | +12.96% |
1 week
2 550.50
2 689.50
1 month
2 513.002 890.00
Current year
2 267.003 014.50
1 year
1 856.003 014.50
3 years
1 708.003 014.50
5 years
1 440.003 014.50
10 years
488.503 014.50
| Managers | Title | Age | Since |
|---|---|---|---|
Toshiaki Takagi
CHM | Chairman | 66 | 81-03-31 |
Naoki Muto
DFI | Director of Finance/CFO | - | - |
Kazuhisa Senshu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shouji Hatano
CMP | Compliance Officer | 64 | 83-03-31 |
Hidenori Nishi
BRD | Director/Board Member | 73 | 20-06-24 |
Shinjiro Sato
BRD | Director/Board Member | 63 | 04-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.24% | 31 M€ | +11.04% | ||
| 1.94% | 31,732 M€ | +14.31% | - | |
| 1.93% | 1,198 M€ | +13.48% | - | |
| 1.90% | 16,729 M€ | +13.38% | - | |
| 1.82% | 67,864 M€ | +14.28% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2,610 | +0.50% | 2 761 500 |
| 24-04-25 | 2,598 | -3.08% | 3,123,200 |
| 24-04-24 | 2,680 | +2.29% | 2,909,700 |
| 24-04-23 | 2,620 | +0.67% | 2,469,300 |
| 24-04-22 | 2,602 | +2.52% | 3,445,000 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).
Calendar
2024-05-13
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
2,598
JPY
Average target price
2,951
JPY
Spread / Average Target
+13.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.96% | 24.8B | |
| -2.92% | 185B | |
| -3.80% | 105B | |
| -5.48% | 66.59B | |
| +11.22% | 54.66B | |
| +16.74% | 47.78B | |
| +4.06% | 41.26B | |
| +4.56% | 26.95B | |
| +1.64% | 26.37B | |
| -1.60% | 24.6B |
- Stock Market
- Equities
- 4543 Stock
